World-class Immuno-Oncology experts to understand cancer immunotherapeutic response, NEX-I is aligned to find the right solution and suggests a new standard for immunotherapy.
2022
12
Showcasing cutting-edge research on resistance mechanisms in a poster presentation at the ESMO I-O Congress
11
Professor Apotolia Maria Tsimberidou, a world-renowned clinical expert in oncology from MD Anderson, joined our distinguished Scientific Advisory Board (SAB)
10
Series-A Funding 22 billion KRW
05
Publication of ONCOKINE™ Discovery Platform, New anticancer immunotherapy strategy technology: Journal of controlled release, (IF=11.467)